Prenetics Global Limited
PREHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Prenetics Global Limited focuses on Diagnostics & Research services and products. Prenetics Global Limited, a health sciences company, focuses on consumer health in Hong Kong and the United States. Valued at $356.5M, PRE is a small-cap name in its sector. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution services for sports nutrition products under the Europa brand.
Market Cap
$356.5M
Beta
0.15
P/E (TTM)
—
P/E (Fwd)
-30.84
EPS (TTM)
$-2.46
EPS (Fwd)
$-0.68
ROE
-22.1%
ROA
-11.4%
Cash
$63.8M
Total Debt
$1.8M
Free CF
-$73.0M
52W Change
133.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $63.8M in cash comfortably exceeding the $1.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$73.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -22.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $13.2M (2022) to $92.4M (2025), reflecting a 602% increase over the period.
With a beta below 0.7, Prenetics Global Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PRE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.